Thibeault Dominic, Gauthier Charles, Legault Jean, Bouchard Jimmy, Dufour Philippe, Pichette André
Laboratoire d'Analyse et de Séparation des Essences Végétales, Département des Sciences Fondamentales, Université du Québec à Chicoutimi, 555 boul. de l'Université, Chicoutimi, Québec, Canada.
Bioorg Med Chem. 2007 Sep 15;15(18):6144-57. doi: 10.1016/j.bmc.2007.06.033. Epub 2007 Jun 20.
Germanicane-type triterpenes allobetulin (3) and 28-oxoallobetulin (4) can be obtained by the Wagner-Meerwein rearrangement of the more available lupane-type triterpenes betulin (1) and betulinic acid (2), respectively. The medical uses of betulinic acid (2) and its derivatives are limited because of their poor hydrosolubility and pharmacokinetics properties. In order to overcome this major problem, we synthesized and studied the in vitro anticancer activity of a series of 3beta-O-monodesmosidic saponins derived from betulin (14-16), betulinic acid (20-22), allobetulin (23-28) and 28-oxoallobetulin (29-34) based on six different natural sugar residues (d-glucose, l-rhamnose, d-arabinose, d-galactose, d-mannose and d-xylose). This structure-activity relationship study confirmed that betulinic acid saponins are generally better in vitro anticancer agents than those derived from betulin with the exception of betulin 3beta-O-alpha-d-mannopyranoside (15) which exerted a potent cytotoxic activity against lung carcinoma (A-549) and colorectal adenocarcinoma (DLD-1) human cell lines with IC(50) ranging from 7.3 to 10.1mumol/L. Furthermore, although the synthesis of novel germanicane-type saponins was carried out with success, the bioactivity measured for these glycosides was not as high as we anticipated since only the 3beta-O-beta-d-glucopyranoside and 3beta-O-beta-d-galactopyranoside of allobetulin (23,24) showed moderate anticancer activity (IC(50) 30-40 micromol/L).
日耳曼烷型三萜类化合物别桦木醇(3)和28-氧代别桦木醇(4)可分别通过更易获得的羽扇豆烷型三萜类化合物桦木醇(1)和桦木酸(2)的瓦格纳-米尔温重排反应得到。桦木酸(2)及其衍生物的医学用途因其水溶性差和药代动力学性质而受到限制。为了克服这一主要问题,我们合成并研究了一系列基于六种不同天然糖残基(d-葡萄糖、l-鼠李糖、d-阿拉伯糖、d-半乳糖、d-甘露糖和d-木糖)的3β-O-单糖苷皂苷的体外抗癌活性,这些皂苷分别衍生自桦木醇(14-16)、桦木酸(20-22)、别桦木醇(23-28)和28-氧代别桦木醇(29-34)。这种构效关系研究证实,除了桦木醇3β-O-α-d-甘露糖苷(15)对肺癌(A-549)和结肠直肠腺癌(DLD-1)人细胞系具有强大的细胞毒活性(IC50范围为7.3至10.1μmol/L)外,桦木酸皂苷通常比源自桦木醇的皂苷具有更好的体外抗癌活性。此外,尽管新型日耳曼烷型皂苷的合成取得了成功,但这些糖苷的生物活性测定结果不如我们预期的高,因为只有别桦木醇的3β-O-β-d-葡萄糖苷和3β-O-β-d-半乳糖苷(23,24)表现出中等的抗癌活性(IC50为30-40μmol/L)。